| JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC (NCT07582822) | Biotech Pharmaceutical Co., Ltd. | 2026-05-30 |
| JY016 Injection in Patients With Advanced Solid Tumors Expressing EGFR (NCT07510841) | Biotech Pharmaceutical Co., Ltd. | 2026-04-30 |
| A Phase Ia Single Ascending-Dose Study of Subcutaneous EB070 Injection in Healthy Volunteers (NCT07413536) | Biotech Pharmaceutical Co., Ltd. | 2026-03-01 |
| A Phase I Clinical Trial of JH013 Injection (NCT06633055) | Biotech Pharmaceutical Co., Ltd. | 2024-10-31 |
| Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NCT05978050) | Biotech Pharmaceutical Co., Ltd. | 2024-08-01 |
| Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer (NCT06343116) | Biotech Pharmaceutical Co., Ltd. | 2024-04-01 |
| A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma (NCT06333821) | Biotech Pharmaceutical Co., Ltd. | 2024-04-01 |
| Safety and Preliminary Clinical Activity of Itolizumab in ARDS (NCT05978544) | Biotech Pharmaceutical Co., Ltd. | 2023-12-31 |
| Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis (NCT05986162) | Biotech Pharmaceutical Co., Ltd. | 2023-12-30 |
| Safety and Clinical Activity of Itolizumab in aGVHD (NCT05823675) | Biotech Pharmaceutical Co., Ltd. | 2023-05-19 |
| A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN (NCT04949503) | Biotech Pharmaceutical Co., Ltd. | 2021-10-08 |
| A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma (NCT06879691) | Biotech Pharmaceutical Co., Ltd. | 2021-05-15 |
| Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children (NCT04532229) | Biotech Pharmaceutical Co., Ltd. | 2021-04-03 |